| Ranked All-Publication list | Historiographs | Glossary HistCite Guide About |
| Nodes: 169, Authors: 715, Journals: 56, Cited References: 4826, Words: 597
Yearly output | Document Type | Language | Institution | Institution with Subdivision | Country |
| View: Overview | Sorted by year, source, volume, issue, page. |
Page 1 of 2: [ 1 2 ]
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
|---|---|---|---|---|---|
| 1 | 1 | 52 | 1 2005 ARCHIVES OF INTERNAL MEDICINE 165 (22): 2651-2658 Chim CS; Kwong YL; Lie AKW; Ma SK; Chan CC; et al. Long-term outcome of 231 patients with essential thrombocythemia - Prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia | 1 | 2 |
| 2 | 1 | 45 | 2 2005 BLOOD 105 (11): 4187-4190 Kaushansky K On the molecular origins of the chronic myeloproliferative disorders: it all makes sense | 24 | 38 |
| 3 | 1 | 24 | 3 2005 BLOOD 106 (4): 1207-1209 Steensma DP; Dewald GW; Lasho TL; Powell HL; McClure RF; et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes | 50 | 63 |
| 4 | 1 | 48 | 4 2005 BLOOD 106 (6): 2162-2168 Jones AV; Kreil S; Zoi K; Waghorn K; Curtis C; et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders | 51 | 56 |
| 5 | 1 | 10 | 5 2005 BLOOD 106 (8): 2920-2921 Scott LM; Campbell PJ; Baxter EJ; Todd T; Stephens P; et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders | 8 | 8 |
| 6 | 3 | 18 | 6 2005 BLOOD 106 (10): 3370-3373 Jelinek J; Oki Y; Gharibyan V; Bueso-Ramos C; Prchal JT; et al. JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia | 23 | 28 |
| 7 | 1 | 21 | 7 2005 BLOOD 106 (10): 3374-3376 Kralovics R; Teo SS; Buser AS; Brutsche M; Tiedt R; et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 | 10 | 11 |
| 8 | 4 | 22 | 8 2005 BLOOD 106 (10): 3377-3379 Levine RL; Loriaux M; Huntly BJP; Loh ML; Beran M; et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia | 18 | 23 |
| 9 | 1 | 74 | 9 2005 BLOOD 106 (13): 4102-4113 Martelli F; Ghinassi B; Panetta B; Alfani E; Gatta V; et al. Variegation of the phenotype induced by the Gatal(low) mutation in mice of different genetic backgrounds | 0 | 0 |
| 10 | 1 | 6 | 10 2005 BRITISH JOURNAL OF HAEMATOLOGY 130 (5): 797-799 Lasho TL; Mesa R; Gilliland DG; Tefferi A Mutation studies in CD3(+), CD19(+) and CD34(+) cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes | 6 | 6 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 11 | 1 | 6 | 11 2005 BRITISH JOURNAL OF HAEMATOLOGY 130 (5): 800-801 Cario H; Goerttler PS; Steimle C; Levine RL; Pahl HL The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera | 2 | 3 |
| 12 | 1 | 8 | 12 2005 BRITISH JOURNAL OF HAEMATOLOGY 130 (6): 964-965 Sulong S; Case M; Minto L; Wilkins B; Hall A; et al. The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia | 3 | 4 |
| 13 | 2 | 7 | 13 2005 BRITISH JOURNAL OF HAEMATOLOGY 130 (6): 968-968 Johan MF; Goodeve AC; Bowen DT; Frew ME; Reilly JT JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia | 4 | 4 |
| 14 | 3 | 27 | 14 2005 BRITISH JOURNAL OF HAEMATOLOGY 131 (2): 166-171 Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; et al. Concomitant neutrophil JAK2(V617F) mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia | 12 | 15 |
| 15 | 2 | 30 | 15 2005 BRITISH JOURNAL OF HAEMATOLOGY 131 (2): 208-213 Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; et al. JAK2(V617F) mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance | 19 | 25 |
| 16 | 5 | 52 | 16 2005 BRITISH JOURNAL OF HAEMATOLOGY 131 (3): 320-328 Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates | 11 | 16 |
| 17 | 1 | 19 | 17 2005 CANCER RESEARCH 65 (20): 9152-9154 Fitzgibbon J; Smith LL; Raghavan M; Smith ML; Debernardi S; et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias | 0 | 5 |
| 18 | 1 | 57 | 18 2005 CELL CYCLE 4 (8): 1053-1056 Tefferi A; Gilliland DG JAK2 in myeloproliferative disorders is not just another kinase | 7 | 12 |
| 19 | 1 | 29 | 19 2005 EXPERIMENTAL HEMATOLOGY 33 (11): 1299-1308 Corre-Buscail I; Pineau D; Boissinot M; Hermouet S Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukin-11 and interleukin-8 | 0 | 0 |
| 20 | 2 | 36 | 20 2005 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 90 (7): 871-874 Cazzola M; Skoda R Gain of function, loss of control - A molecular basis for chronic myeloproliferative disorders | 8 | 8 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 21 | 1 | 178 | 21 2005 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 90 (7): 949-968 Chalandon Y; Schwaller J Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies | 0 | 5 |
| 22 | 4 | 10 | 22 2005 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 90 (12): 1696-1697 McLornan DP; Percy MJ; Jones AV; Cross NCP; McMullin MF Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation | 2 | 2 |
| 23 | 4 | 19 | 23 2005 HEMATOLOGICAL ONCOLOGY 23 (3-4): 91-93 Percy MJ; McMullin MF The V617F JAK2 mutation and the myeloproliferative disorders | 1 | 2 |
| 24 | 4 | 78 | 24 2005 HEMATOLOGY 10: 215-223 Michiels JJ Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond | 4 | 4 |
| 25 | 1 | 90 | 25 2005 INTERNATIONAL JOURNAL OF HEMATOLOGY 82 (2): 85-92 Kiyoi H; Yanada M; Ozeki K Clinical significance of FLT3 in leukemia | 0 | 1 |
| 26 | 1 | 94 | 26 2005 INTERNATIONAL JOURNAL OF HEMATOLOGY 82 (2): 93-99 Choudhary C; Muller-Tidow C; Berdel WE; Serve H Signal transduction of oncogenic Flt3 | 1 | 1 |
| 27 | 1 | 32 | 27 2005 JOURNAL OF BIOLOGICAL CHEMISTRY 280 (24): 22788-22792 Zhao RX; Xing S; Li Z; Fu XQ; Li QS; et al. Identification of an acquired JAK2 mutation in Polycythemia vera | 55 | 56 |
| 28 | 1 | 61 | 28 2005 JOURNAL OF BIOLOGICAL CHEMISTRY 280 (29): 27251-27261 Royer Y; Staerk J; Costuleanu M; Courtoy PJ; Constantinescu SN Janus kinases affect thrombopoietin receptor cell surface localization and stability | 6 | 11 |
| 29 | 2 | 41 | 29 2005 JOURNAL OF BIOLOGICAL CHEMISTRY 280 (51): 41893-41899 Staerk J; Kallin A; Demoulin JB; Vainchenker W; Constantinescu SN JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation - Cross-talk with IGF1 receptor | 8 | 9 |
| 30 | 1 | 84 | 30 2005 JOURNAL OF CLINICAL INVESTIGATION 115 (10): 2618-2624 Amaravadi R; Thompson CB The survival kinases Akt and Pim as potential pharmacological targets | 0 | 12 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 31 | 2 | 108 | 31 2005 JOURNAL OF CLINICAL INVESTIGATION 115 (12): 3339-3347 Kaushansky K The molecular mechanisms that control thrombopoiesis | 0 | 5 |
| 32 | 1 | 79 | 32 2005 JOURNAL OF CLINICAL INVESTIGATION 115 (12): 3370-3377 Macaulay IC; Carr P; Gusnanto A; Ouwehand WH; Fitzgerald D; et al. Platelet genomics and proteomics in human heat and disease | 0 | 4 |
| 33 | 1 | 189 | 33 2005 JOURNAL OF CLINICAL ONCOLOGY 23 (26): 6285-6295 Frohling S; Scholl C; Gilliland DG; Levine RL Genetics of myeloid malignancies: Pathogenetic and clinical implications | 2 | 14 |
| 34 | 3 | 29 | 34 2005 LANCET 366 (9501): 1945-1953 Campbell PJ; Scott LM; Buck G; Wheatley K; East CL; et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study | 16 | 25 |
| 35 | 1 | 80 | 35 2005 LEUKEMIA 19 (10): 1739-1744 Delaval B; Lelievre H; Birnbaum D Myeloproliferative disorders: the centrosome connection | 0 | 3 |
| 36 | 1 | 8 | 36 2005 LEUKEMIA 19 (10): 1843-1844 Tono C; Xu G; Toki T; Takahashi Y; Sasaki S; et al. JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia | 2 | 2 |
| 37 | 2 | 8 | 37 2005 LEUKEMIA 19 (10): 1847-1849 Antonioli E; Guglielmelli P; Pancrazzi A; Bogani C; Verrucci M; et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia | 14 | 17 |
| 38 | 2 | 7 | 38 2005 LEUKEMIA 19 (12): 2359-2360 Ohyashiki K; Aota Y; Akahane D; Gotoh A; Miyazawa K; et al. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients | 5 | 7 |
| 39 | 1 | 18 | 39 2005 M S-MEDECINE SCIENCES 21 (6-7): 669-670 Ugo V; James C; Vainchenker W A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | 0 | 0 |
| 40 | 1 | 175 | 40 2005 MAYO CLINIC PROCEEDINGS 80 (7): 947-958 Tefferi A; Gilliland DG The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Status report and immediate implications for disease classification and diagnosis | 14 | 24 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 41 | 1 | 208 | 41 2005 MAYO CLINIC PROCEEDINGS 80 (9): 1220-1232 Tefferi A; Barbui T bcr/abl-negative, classic myeloproliferative disorders: Diagnosis and treatment | 1 | 3 |
| 42 | 3 | 39 | 42 2005 MOLECULAR INTERVENTIONS 5 (4): 211-215 Pesu M; O'Shea J; Hennighausen L; Silvennoinen O Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders | 3 | 3 |
| 43 | 0 | 47 | 43 2005 NEW ENGLAND JOURNAL OF MEDICINE 352 (17): 1779-1790 Kralovics R; Passamonti F; Buser AS; Teo S; Tiedt R; et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders | 168 | 168 |
| 44 | 1 | 15 | 44 2005 NEW ENGLAND JOURNAL OF MEDICINE 353 (1): 85-86 Barbui T; Finazzi G When and how to treat essential thrombocythemia | 1 | 6 |
| 45 | 1 | 123 | 45 2005 NEW ENGLAND JOURNAL OF MEDICINE 353 (2): 172-187 Krause DS; Van Etten RA Tyrosine kinases as targets for cancer therapy | 3 | 54 |
| 46 | 2 | 5 | 46 2005 NEW ENGLAND JOURNAL OF MEDICINE 353 (13): 1416-1417 Tefferi A; Lasho TL; Gilliland G JAK2 mutations in myeloproliferative disorders | 3 | 5 |
| 47 | 1 | 8 | 47 2005 ONCOGENE 24 (48): 7125-7126 Mahon FX JAK the trigger | 0 | 1 |
| 48 | 1 | 78 | 48 2005 PATHOLOGY 37 (6): 479-492 Jack A Organisation of neoplastic haematopathology services: a UK perspective | 0 | 1 |
| 49 | 2 | 36 | 49 2005 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 102 (52): 18962-18967 Lu XH; Levine R; Tong W; Wernig G; Pikman Y; et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation | 8 | 9 |
| 50 | 3 | 28 | 50 2005 SEMINARS IN HEMATOLOGY 42 (4): 181-183 Skoda R; Prchal JT Chronic myeloproliferative disorders - Introduction | 2 | 2 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 51 | 1 | 109 | 51 2005 SEMINARS IN HEMATOLOGY 42 (4): 196-205 Bench AJ; Pahl HL Chromosomal abnormalities and molecular markers in myeloproliferative disorders | 5 | 6 |
| 52 | 3 | 191 | 52 2005 SEMINARS IN HEMATOLOGY 42 (4): 206-220 Tefferi A; Spivak JL Polycythemia vera: Scientific advances and current practice | 6 | 7 |
| 53 | 3 | 85 | 53 2005 SEMINARS IN HEMATOLOGY 42 (4): 221-229 Zhao ZJ; Vainchenker W; Krantz SB; Casadevall N; Constantinescu SN Role of tyrosine kinases and phosphatases in Polycythemia vera | 3 | 3 |
| 54 | 1 | 80 | 54 2005 SEMINARS IN HEMATOLOGY 42 (4): 230-238 Finazzi G; Harrison C Essential thrombocythemia | 5 | 8 |
| 55 | 1 | 104 | 55 2005 SEMINARS IN HEMATOLOGY 42 (4): 248-258 Barosi G; Hoffman R Idiopathic myelofibrosis | 2 | 2 |
| 56 | 3 | 81 | 56 2005 SEMINARS IN HEMATOLOGY 42 (4): 266-273 Skoda R; Prchal JT Lessons from familial myeloproliferative disorders | 4 | 4 |
| 57 | 1 | 5 | 57 2005 SEMINARS IN ONCOLOGY 32 (4): 357-358 Odenike O Myelofibrosis with myeloid metaplasia: Where is the biology leading us? | 0 | 0 |
| 58 | 1 | 118 | 58 2005 SEMINARS IN ONCOLOGY 32 (4): 422-431 Odenike O; Tefferi A Conventional and new treatment options for myelofibrosis with myeloid metaplasia | 0 | 0 |
| 59 | 6 | 69 | 59 2005 TRENDS IN MOLECULAR MEDICINE 11 (12): 546-554 James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects | 8 | 9 |
| 60 | 1 | 86 | 60 2005 VIRCHOWS ARCHIV 447 (6): 909-919 Fend F; Bock O; Kremer M; Specht K; Quintanilla-Martinez L Ancillary techniques in bone marrow pathology: molecular diagnostics on bone marrow trephine biopsies | 1 | 2 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 61 | 2 | 31 | 61 2005 VIRCHOWS ARCHIV 447 (6): 947-953 Siebolts U; Ates M; Spitz R; Thiele J; Wickenhauser C Quantification of clonal hematopoiesis in polycythemia vera | 0 | 0 |
| 62 | 15 | 28 | 62 2006 AMERICAN JOURNAL OF CLINICAL PATHOLOGY 125 (4): 625-633 Murugesan G; Aboudola S; Szpurka H; Verbic MA; Maciejewski JP; et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis | 1 | 1 |
| 63 | 7 | 12 | 63 2006 AMERICAN JOURNAL OF CLINICAL PATHOLOGY 125 (5): 651-653 Greiner TC Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders | 0 | 0 |
| 64 | 4 | 38 | 64 2006 AMERICAN JOURNAL OF PATHOLOGY 169 (2): 471-481 Bock O; Neuse J; Hussein K; Brakensiek K; Buesche G; et al. Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status | 0 | 0 |
| 65 | 4 | 35 | 65 2006 ANNALES DE BIOLOGIE CLINIQUE 64 (1): 3-9 Pargade V; Darnige L; Gaussem P Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera | 0 | 0 |
| 66 | 4 | 68 | 66 2006 ANNALS OF HEMATOLOGY 85 (4): 226-232 Thiele J; Kvasnicka HM Grade of bone marrow fibrosis is associated with relevant hematological findings - a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis | 0 | 0 |
| 67 | 13 | 25 | 67 2006 ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE 130 (7): 997-1003 Olsen RJ; Tang ZW; Farkas DH; Bernard DW; Zu YL; et al. Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system | 0 | 1 |
| 68 | 25 | 152 | 68 2006 ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE 130 (8): 1126-1132 Cao M; Olsen RJ; Zu YL Polycythemia vera - New clinicopathologic perspectives | 0 | 0 |
| 69 | 4 | 101 | 69 2006 ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE 130 (8): 1133-1143 Ahmed A; Chang CC Chronic idiopathic myelofibrosis - Clinicopathologic features, pathogenesis, and prognosis | 0 | 0 |
| 70 | 10 | 94 | 70 2006 ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE 130 (8): 1144-1150 Sanchez S; Ewton A Essential thrombocythemia - A review of diagnostic and pathologic features | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 71 | 1 | 29 | 71 2006 BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 19 (3): 361-364 Tefferi A Classic and atypical myeloproliferative disorders - Preface | 0 | 0 |
| 72 | 1 | 232 | 72 2006 BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 19 (3): 365-385 Tefferi A; Gilliland G Classification of chronic myeloid disorders: From Dameshek towards a semi-molecular system | 0 | 0 |
| 73 | 4 | 44 | 73 2006 BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 19 (3): 387-397 Chen G; Prchal JT Polycythemia vera and its molecular basis: An update | 0 | 0 |
| 74 | 1 | 72 | 74 2006 BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 19 (3): 399-412 Chagraoui H; Wendling F; Vainchenker W Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models | 0 | 0 |
| 75 | 1 | 121 | 75 2006 BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 19 (3): 455-469 Tefferi A The diagnosis of polycythemia vera: New tests and old dictums | 0 | 0 |
| 76 | 3 | 103 | 76 2006 BIOCHEMICAL PHARMACOLOGY 71 (6): 713-721 Valentino L; Pierre J JAW/STAT signal transduction: Regulators and implication in hematological malignancies | 1 | 2 |
| 77 | 2 | 72 | 77 2006 BLOOD 107 (3): 907-915 Zhao W; Kitidis C; Fleming MD; Lodish HF; Ghaffari S Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway | 0 | 3 |
| 78 | 3 | 7 | 78 2006 BLOOD 107 (3): 1237-1238 Sattler M; Watz C; Crowley BJ; Lengfelder E; Janne PA; et al. A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples | 0 | 0 |
| 79 | 4 | 16 | 79 2006 BLOOD 107 (4): 1733-1734 Steensma DP; Pardanani A More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders | 0 | 0 |
| 80 | 1 | 9 | 80 2006 BLOOD 107 (4): 1735-1735 Stevenson WS; Hoyt R; Kiu H; Grigg AP; Szer J; et al. Point mutations in MYB and the KIX domain of EP300 are uncommon in the human myeloproliferative disorders | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 81 | 2 | 9 | 81 2006 BLOOD 107 (5): 2098-2100 Campbell PJ; Griesshammer M; Dohner K; Dohner H; Kusec R; et al. V617F mutation in JAK2 is associated idiopathic myelofibrosis | 2 | 3 |
| 82 | 3 | 34 | 82 2006 BLOOD 107 (6): 2525-2530 Corazza F; Hermans C; D'Hondt S; Ferster A; Kentos A; et al. Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia | 1 | 1 |
| 83 | 3 | 22 | 83 2006 BLOOD 107 (8): 3339-3341 Jones AV; Silver RT; Waghorn K; Curtis C; Kreil S; et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha | 1 | 2 |
| 84 | 3 | 8 | 84 2006 BLOOD 107 (9): 3422-3423 Walczak H Polycythemia vera erythroblasts: too tough to die | 0 | 0 |
| 85 | 3 | 52 | 85 2006 BLOOD 107 (9): 3495-3502 Zeuner A; Pedini F; Signore M; Ruscio G; Messina C; et al. Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells | 1 | 1 |
| 86 | 6 | 34 | 86 2006 BLOOD 107 (9): 3676-3682 Passamonti F; Rumi E; Pietra D; Della Porta MG; Boveri E; et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34(+) cells into peripheral blood in myeloproliferative disorders | 4 | 4 |
| 87 | 4 | 19 | 87 2006 BLOOD 107 (10): 4139-4141 Levine RL; Belisle C; Wadleigh M; Zahrieh D; Lee S; et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and NIMM patients with clonal hematopoiesis | 2 | 2 |
| 88 | 10 | 108 | 88 2006 BLOOD 107 (11): 4214-4222 Schafer AI Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia | 0 | 0 |
| 89 | 5 | 25 | 89 2006 BLOOD 107 (11): 4274-4281 Wernig G; Mercher T; Okabe R; Levine RL; Lee BH; et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model | 4 | 4 |
| 90 | 1 | 45 | 90 2006 BLOOD 107 (11): 4326-4333 Wierenga ATJ; Schepers H; Moore MAS; Vellenga E; Schuringa JJ STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBP alpha | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 91 | 1 | 80 | 91 2006 BLOOD 108 (1): 123-133 Liu Y; Pop R; Sadegh C; Brugnara C; Haase VH; et al. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo | 0 | 0 |
| 92 | 1 | 66 | 92 2006 BLOOD 108 (1): 184-191 Cokic VP; Beleslin-Cokic BB; Tomic M; Stojilkovic SS; Noguchi CT; et al. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells | 0 | 0 |
| 93 | 8 | 31 | 93 2006 BLOOD 108 (1): 346-352 Bellanne-Chantelot C; Chaumarel I; Labopin M; Bellanger F; Barbu V; et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders | 0 | 0 |
| 94 | 3 | 6 | 94 2006 BRITISH JOURNAL OF HAEMATOLOGY 132 (2): 244-245 Cheung B; Radia D; Pantelidis P; Yadegarfar G; Harrison C The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia | 1 | 1 |
| 95 | 1 | 41 | 95 2006 BRITISH JOURNAL OF HAEMATOLOGY 134 (1): 27-36 Rinaldi A; Kwee I; Poretti G; Mensah A; Pruneri G; et al. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas | 0 | 0 |
| 96 | 1 | 6 | 96 2006 BRITISH JOURNAL OF HAEMATOLOGY 134 (3): 341-343 Ma W; Kantarjian H; Verstovsek S; Jilani I; Gorre M; et al. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour | 0 | 0 |
| 97 | 36 | 212 | 97 2006 BRITISH JOURNAL OF HAEMATOLOGY 134 (4): 366-384 Khwaja A The role of Janus kinases in haemopoiesis and haematological malignancy | 0 | 0 |
| 98 | 4 | 14 | 98 2006 CANCER 106 (3): 631-635 Tefferi A; Lasho TL; Schwager SM; Strand JS; Elliott M; et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2(V617F) in polycythemia vera | 5 | 5 |
| 99 | 6 | 66 | 99 2006 CANCER CELL 10 (1): 65-75 Walters DK; Mercher T; Gu TL; O'Hare T; Tyner JW; et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia | 0 | 0 |
| 100 | 1 | 54 | 100 2006 CANCER CELL 10 (1): 77-87 Kovacic B; Stoiber D; Moriggl R; Weisz E; Ott RG; et al. STAT1 acts as a tumor promoter for leukemia development | 0 | 0 |
Page 1 of 2: [ 1 2 ]
Generated by HistCite 2006.08.14